January 22, 2018 |
Molecular Breast Imaging Provides Accurate Identification of Tumors in Women with Dense Breasts, Implants
September 9, 2013  | 

Houston, TX – St. Luke’s Medical Center is proud to offer a Molecular Breast Imaging (MBI) device that is sensitive enough to detect even tiny tumors. The Discovery NM 750b, from GE Healthcare, is designed to help improve detection of breast cancer, even in women with dense breasts where results of mammography may be inconclusive.

“The Discovery system is an important advancement in the early detection and diagnosis of breast cancer, but for women with dense breasts, it could truly be a lifesaver,” said Eric J. Ladwig, Operations Manager, Nuclear Medicine at St. Luke’s Medical Center. “Women with dense breasts have an increased risk of breast cancer and this condition can impact the quality of a traditional mammogram. MBI is not affected by breast density, resulting in a clear image and great confidence that the patient is cancer free or truly needs to have a biopsy.”

MBI is a comfortable examination, as only light immobilization pressure is required during studies versus a traditional mammography.

During a Molecular Breast Imaging procedure with The Discovery, a patient receives a tracer injection that locates metabolically active tumors by blood flow. Since the tumor metabolizes the isotope to a higher degree than normal tissue, it will appear as a “hot spot” on the scan.

Visit: St. Luke’s Medical Center Continue>

Page | 1 2
Suggested Articles